Practical Solution PCL
SET:TPS
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
P
|
Practical Solution PCL
SET:TPS
|
TH |
|
Charles River Laboratories International Inc
NYSE:CRL
|
US |
|
P
|
Petronor E&P ASA
OSE:PNOR
|
NO |
|
J
|
Jay Bharat Maruti Ltd
NSE:JAYBARMARU
|
IN |
|
Qianjiang Yongan Pharmaceutical Co Ltd
SZSE:002365
|
CN |
Balance Sheet
Balance Sheet Decomposition
Practical Solution PCL
Practical Solution PCL
Balance Sheet
Practical Solution PCL
| Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||
| Cash & Cash Equivalents |
94
|
50
|
17
|
10
|
198
|
122
|
150
|
0
|
0
|
184
|
|
| Cash |
94
|
50
|
17
|
10
|
198
|
0
|
0
|
0
|
0
|
0
|
|
| Cash Equivalents |
0
|
0
|
0
|
0
|
0
|
122
|
150
|
0
|
0
|
184
|
|
| Short-Term Investments |
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
160
|
176
|
217
|
177
|
134
|
179
|
196
|
578
|
650
|
708
|
|
| Accounts Receivables |
144
|
147
|
167
|
143
|
117
|
161
|
166
|
516
|
558
|
640
|
|
| Other Receivables |
16
|
30
|
50
|
35
|
16
|
18
|
30
|
62
|
92
|
68
|
|
| Inventory |
33
|
74
|
35
|
57
|
47
|
45
|
129
|
103
|
86
|
38
|
|
| Other Current Assets |
2
|
6
|
4
|
16
|
30
|
2
|
3
|
5
|
10
|
15
|
|
| Total Current Assets |
295
|
306
|
273
|
260
|
408
|
348
|
477
|
742
|
875
|
945
|
|
| PP&E Net |
11
|
10
|
18
|
72
|
145
|
163
|
161
|
168
|
162
|
155
|
|
| PP&E Gross |
11
|
10
|
18
|
72
|
145
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
20
|
19
|
18
|
21
|
24
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
5
|
|
| Note Receivable |
0
|
8
|
10
|
3
|
25
|
46
|
78
|
103
|
106
|
83
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
14
|
32
|
27
|
46
|
53
|
58
|
58
|
83
|
128
|
254
|
|
| Total Assets |
320
N/A
|
357
+12%
|
328
-8%
|
381
+16%
|
632
+66%
|
616
-3%
|
774
+26%
|
1 099
+42%
|
1 275
+16%
|
1 441
+13%
|
|
| Liabilities | |||||||||||
| Accounts Payable |
85
|
94
|
73
|
99
|
113
|
149
|
203
|
253
|
282
|
250
|
|
| Accrued Liabilities |
23
|
25
|
27
|
31
|
23
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
0
|
0
|
40
|
|
| Current Portion of Long-Term Debt |
1
|
1
|
3
|
2
|
9
|
4
|
4
|
20
|
25
|
24
|
|
| Other Current Liabilities |
99
|
73
|
40
|
26
|
21
|
12
|
54
|
122
|
99
|
228
|
|
| Total Current Liabilities |
207
|
194
|
143
|
159
|
165
|
164
|
263
|
395
|
406
|
542
|
|
| Long-Term Debt |
2
|
1
|
5
|
4
|
31
|
6
|
6
|
35
|
39
|
19
|
|
| Minority Interest |
0
|
0
|
0
|
0
|
0
|
3
|
2
|
7
|
16
|
15
|
|
| Other Liabilities |
4
|
5
|
9
|
32
|
55
|
66
|
98
|
101
|
121
|
155
|
|
| Total Liabilities |
214
N/A
|
200
-6%
|
156
-22%
|
196
+25%
|
252
+28%
|
239
-5%
|
369
+55%
|
539
+46%
|
581
+8%
|
731
+26%
|
|
| Equity | |||||||||||
| Common Stock |
40
|
80
|
80
|
100
|
140
|
140
|
168
|
177
|
210
|
210
|
|
| Retained Earnings |
66
|
77
|
91
|
85
|
87
|
84
|
84
|
218
|
279
|
293
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
153
|
153
|
153
|
166
|
212
|
212
|
|
| Unrealized Security Profit/Loss |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Treasury Stock |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
2
|
6
|
4
|
|
| Total Equity |
106
N/A
|
157
+48%
|
171
+9%
|
185
+8%
|
380
+106%
|
377
-1%
|
405
+7%
|
559
+38%
|
694
+24%
|
710
+2%
|
|
| Total Liabilities & Equity |
320
N/A
|
357
+12%
|
328
-8%
|
381
+16%
|
632
+66%
|
616
-3%
|
774
+26%
|
1 099
+42%
|
1 275
+16%
|
1 441
+13%
|
|
| Shares Outstanding | |||||||||||
| Common Shares Outstanding |
80
|
192
|
192
|
240
|
336
|
336
|
336
|
354
|
417
|
418
|
|